TLR4/CD14 Inhibitors IAXO (synthetic)

Lipid A from E. coli


General Information

IAXOTM compounds are Glycolipids and Benzylammonium Lipids, analogues of lipid A that are designed to act as
Toll-like-receptor 4/TLR4 antagonists that interfere with CD14 and TLR4 ligand binding in vivo and in vitro.

IAXO's represent innovative drug candidates with therapeutic activity in rodent models of (auto/sterile)
​​​​​​​inflammatory diseases, such as neuropathic pain.

Viewing 1 — 5 of 5 items | Page 1 of 1
  • IAXO-101 (CD14/TLR4 Antagonist) (synthetic)

    IAXO-101 (CD14/TLR4 Antagonist) (synthetic)

    £140.16
    The novel IAXO classes of glycolipid and benzylammonium lipids are synthetic TLR4/CD14 ligands with TLR4 modulating activities in vitro, and conferring protection against TLR4/CD14-mediated tissue damage and inflammation in vivo.
  • IAXO-102 (CD14/TLR4 Antagonist) (synthetic)

    IAXO-102 (CD14/TLR4 Antagonist) (synthetic)

    £140.16
    The novel IAXO classes of glycolipid and benzylammonium lipids are synthetic TLR4/CD14 ligands with TLR4 modulating activities in vitro, and conferring protection against TLR4/CD14-mediated tissue damage and inflammation in vivo.
  • IAXO-103 (CD14/TLR4 Antagonist) (synthetic)

    IAXO-103 (CD14/TLR4 Antagonist) (synthetic)

    £140.16
    The novel IAXO classes of glycolipid and benzylammonium lipids are synthetic TLR4/CD14 ligands with TLR4 modulating activities in vitro, and conferring protection against TLR4/CD14-mediated tissue damage and inflammation in vivo.
  • IAXO-201 (Control for IAXO-102) (synthetic)

    IAXO-201 (Control for IAXO-102) (synthetic)

    £140.16
    The novel IAXO classes of glycolipid and benzylammonium lipids are synthetic TLR4/CD14 ligands with TLR4 modulating activities in vitro, and conferring protection against TLR4/CD14-mediated tissue damage and inflammation in vivo.
Viewing 1 — 5 of 5 items | Page 1 of 1